AbbVie Inc ABBV
News
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
AbbVie Reports First-Quarter 2024 Financial Results
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Medincell, AbbVie to Co-Develop Injectable Therapeutics
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
AbbVie on Pace for Largest Percent Decrease Since October 2023 — Data Talk
AbbVie to Host First-Quarter 2024 Earnings Conference Call
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®